Vaxcyte, Inc. (PCVX) — Stock Valuation & Research

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and…

PCVX key statistics

Price$60.98
Market cap$9.6B
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range39.87-90.75
Beta1.29

Explore PCVX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.